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The relative immaturity of the neonatal immune system limits CD4 Th1 and cytotoxic T lymphocyte (CTL) responses, and
represents a significant challenge for the development of vaccines against intracellular pathogens. In this report, we
demonstrate the ability of a non-replicative delivery system based on parvovirus-like particles (VLP) to induce CTL responses
in the neonatal period. A single immunization of 1-week-old BALB/c mice with recombinant VLP carrying a CD8 T cell
determinant from lymphocytic choriomeningitis virus (VLP-LCMV) induced antigen-specific CD8 cytotoxic T cells that were
similar to those elicited by adult immunization, as assessed by cytotoxic activity, interferon (IFN)- secretion, cytotoxic
precursor cell frequencies, in vitro avidity for antigen and protective activity against viral challenge. These CTL responses
are elicited within 2 weeks of a single immunization, in the absence of adjuvant and independently of the presence and helpate va
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INTRODUCTION
The immaturity of the immune system poses severe
challenges for the induction of protective immune re-
sponses in early life. Antibody responses elicited by
neonatal and infant immunization are quantitatively lim-
ited, both in humans and in mice, and may be further
inhibited by antibodies of maternal origin (Siegrist, 2001).
Early-life T cell responses, although more readily in-
duced than previously considered, and less susceptible
to inhibition by maternal antibodies, also differ from adult
responses (Adkins, 1999; Garcia et al., 2001; Siegrist,
2001). In early-life murine models, limited CD4 Th1 and
CD8 cytotoxic T cell (CTL) responses were observed
following infection (Sarzotti et al., 1996) or after immuni-
zation with conventional measles or hepatitis B vaccines
(Barrios et al., 1996b; Brazolot Millan et al., 1998). In
human infants, disease severity of neonatal herpesvirus
infection is associated with limited interferon (IFN)-
responses (Burchett et al., 1992; Hayward et al., 1984),
and the higher relative risk of chronicity following acute
hepatitis B infection in infants and young children re-
flects their failure to clear virus (Hyams, 1995). Data on
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infant T cell responses to immunization is still scarce.
Although BCG immunization induces adult-like neonatal
IFN- responses (Vekemans et al., 2001), IL-12 and IFN-
responses to live attenuated measles vaccine remain
limited up to one year of age, as compared to adults
(Gans et al., 2001; Gans et al., 1999). Altogether, these
observations identified limitations of CD4 Th1 and CTL
responses as characteristic features of neonatal immu-
nity. This has been suggested to reflect a preferential
differentiation of early-life T cell responses toward the
Th2 pathway, as a “default” developmental pathway
(Fadel and Sarzotti, 2000; Adkins, 2000).
These limitations represent a significant challenge for
the development of vaccines against important intracel-
lular pathogens, including tuberculosis, malaria and HIV,
such that there is a requirement for novel antigen deliv-
ery systems able to induce adult-like CD4 Th1 and CTL
responses in early life. In the last few years, DNA vac-
cines (Bot, 2000), live replicating vaccines (Franchini et
al., 2001; Kovarik et al., 2001; Siegrist, 2001), and a few
strong Th1-driving adjuvants (Barrios et al., 1996a; Bra-
zolot Millan et al., 1998; Forsthuber et al., 1996; Kovarik et
al., 1999) were found to ameliorate these limitations. It
was thus suggested that the induction of adult-like CD4
Th1 and CTL neonatal responses essentially depends on
the extent of neonatal APC activation and/or of neonatal
APC-T cell interactions (Adkins, 1999). Whether the mainof CD4 T cells, highlighting the potential of VLP as candid
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challenge is that of a higher activation threshold of neo-
natal APC, of suboptimal CD4 T cell neonatal re-
sponses (Brugnoni et al., 1994; Durandy et al., 1995;
Fuleihan et al., 1994; Nonoyama et al., 1995) and/or of
other determinants of neonatal APC-T cell interactions is
currently unknown.
A novel non-replicative virus-like particle (VLP) deliv-
ery system, based on the self-assembly of the modified
porcine parvovirus (PPV-VLP) VP2 capsid protein, was
recently reported as inducing strong MHC class I-re-
stricted CTL responses in adult mice, in the absence of
adjuvant, independently of CD4 T cell help (Sedlik et al.,
1997), and thus likely resulting from direct APC matura-
tion/activation (Bennett et al., 1998; Moron et al., 2002;
Schoenberger et al., 1998). We used this delivery system
to test whether non-replicative antigens can induce neo-
natal CTL responses, and to evaluate the requirement of
CD4 T cell help in the induction of neonatal CTL re-
sponses. Experiments were performed with PPV-VLP into
which the LCMV118–132 peptide, which contains both a
weak MHC class II-restricted and a strong immunodom-
inant MHC class I-restricted determinant from the LCMV
nucleoprotein of the WE strain (Aichele et al., 1990; Fay-
olle et al., 1996), was inserted (VLP-LCMV). Comparative
analyses of humans and mice have indicated that the
stage of immune maturation that prevails during the
neonatal period (defined as 28 days in humans) is best
approximated by that of 1-week-old mice (Siegrist, 2001).
Induction of anti-viral CD8 T cell responses and protec-
tive efficacy against viral challenge were therefore com-
pared following VLP-LCMV immunization of 1-week-old
and adult mice, in presence or absence of CD4 T cells.
RESULTS
Induction of adult-like bulk cytotoxic responses by
neonatal VLP-LCMV immunization
BALB/c mice were immunized i.p. at the age of 1 week
and as adult controls with a single dose (10 g) of
VLP-LCMV or control VLP (VLP-ctrl). Neonatal immuniza-
tion was well tolerated and did not affect weight gain, a
sensitive marker of vaccine-induced toxicity in early life.
Two weeks after priming, splenocytes were restimulated
for 5 days in vitro with the LCMV118–132 peptide and as-
sessed for their capacity to lyse LCMV118–132-pulsed P815
target cells. A strong CTL response was observed both
in mice immunized at the age of 1 week and in adult
controls, whereas no lysis was observed with spleno-
cytes from mice immunized with VLP-ctrl (Fig. 1), or on
target cells pulsed with a control peptide, a CTL deter-
minant from measles virus hemagglutinin (MVHA544–552,
not shown). As P815 target cells do not express MHC
class II nor are susceptible to NK cell lysis, CD4 T cells
and NK cells are unlikely to contribute significantly to the
observed cytotoxicity. Since CTL responses against
LCMV118–132 even in adults require repeated injection of
the peptide with adjuvant (iFA or cFA) (Fayolle et al.,
1991), the observed CTL responses after single immuni-
zation without adjuvant are likely to be due to the PPV-
VLP antigen delivery system.
Similar frequencies and avidity of antigen-specific
effector cells induced in 1-week-old and adult mice
CTL responses were characterized and quantified by
limiting dilution analysis (LDA) and assessment of the
frequency of IFN--producing cells by ELISPOT. LDA
performed 2 weeks after immunization indicated that the
frequency of precursors developing into cytotoxic effec-
tors (CTLp) was high (1/10,000) both in mice immu-
nized with VLP-LCMV at 1 week of age and as adults
(Table 1), whereas frequencies remained lower than
1/50,000 following VLP-ctrl immunization. Although the
frequency of CTLp varied between LDA experiments, a
threefold lower CTLp frequency (expressed per total
spleen cells) was consistently observed following neo-
natal immunization (P  0.05). Quantification of the total
number of CTLp per spleen confirmed that, 2 weeks after
priming, the number of LCMV-specific CTLp was three-
fold lower following neonatal compared to adult immu-
nization (Table 1). However, flow cytometric analysis in-
dicated that CD8 T cells present in the spleen of
3-week-old BALB/c mice (i.e., at the time of evaluation of
CD8 T cell responses) represent 5–7% of total spleno-
cytes, compared to 11–13% in adult mice (data not
shown). Thus, the frequency within the CD8 T cell
subset of splenocytes able to generate cytotoxic effec-
tors against LCMV118–132 was not significantly different
following early-life and adult VLP-LCMV immunization
(Table 1).
FIG. 1. CD8T cell cytotoxic responses to neonatal and adult VLP-
LCMV immunization. One-week-old and adult BALB/c mice were im-
munized i.p. with 10 g of VLP-LCMV or VLP-ctrl. Two weeks after
immunization, splenocytes were harvested, pooled by immunization
groups and restimulated in vitro for 5 days with the LCMV118–132 peptide.
Cytotoxic activity was measured with 51Cr-labeled P815 targets cells
pulsed with 50 M of LCMV118–132 peptide (P815- LCMV118–132), or incu-
bated with medium alone (P815-medium). Data represent the means of
percent specific lysis ((% lysis P815-LCMV118–132)  (% lysis P815-medi-
um)) from duplicate wells obtained at each effector/target ratio. Results
are from 1 of 3 representative experiments. Lysis of uncoated target
cells by all effectors was less than 10% at all E:T ratios and is not
shown.
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Similar results were obtained by IFN- ELISPOT anal-
ysis. Under our experimental conditions, ex vivo ELISPOT
analyses did not detect any LCMV118–132-specific IFN-
spot forming cell (SFC) 2 weeks after a single immuni-
zation of adult or 1-week-old mice. This is in contrast to
a previous report where immunization included the ad-
ministration of 2 vaccine doses to adult mice (Sedlik
et al., 1997). However, similarly high frequencies of
LCMV118–132-specific IFN- SFC in both age groups were
observed after bulk in vitro restimulation of splenocytes
with the LCMV118–132 peptide (Fig. 2). Since LCMV118–132
comprises both an MHC class II- as well as an MHC
class I-restricted determinant, it was important to define
the cell subset responsible for this IFN--secretion. De-
pletion of CD8 T cells during in vitro restimulation ab-
rogated IFN- responses, confirming CD8 T cells as the
source of IFN--SFC in neonatally immunized mice (Fig.
2), as previously observed in adults (Sedlik et al., 2000).
Immunization with VLP-ctrl did not elicit IFN--producing
LCMV118–132-specific T cells (Fig. 2). IL-5-producing LCMV-
specific SFC were not observed in mice from any group
(not shown).
Since the in vivo efficiency of CTL does not only de-
pend on CTL numbers but also on their avidity for their
antigen-bearing target (Alexander-Miller et al., 1996; Sed-
lik et al., 2000), we next compared the capacity of adult
and neonatal effector cells to lyse P815 targets cells
pulsed with a range of LCMV118–132 concentrations. As
shown in Fig. 3, immunization with VLP-LCMV primed
early-life CTL whose restimulated effector cells were of
similar avidity for antigen-pulsed targets as in adults.
Previous experiments comparing in vitro CTL avidity of
adult mice immunized with various antigen delivery sys-
tems have indicated that this reactivity profile reflects a
strong avidity for target cells and correlates with in vivo
protection (Sedlik et al., 2000).
TABLE 1
CTLp Frequencies after VLP-LCMV Immunizationa
CTLp
frequencyb
Total
CTLp/spleenc
CTLp/CD8
T cellsc
Exp 1: VLP-LCMV
1 week 1/5227 12627 1/261
Adults 1/1597 55103 1/192
Exp 2: VLP-LCMV
1 week 1/4509 14194 1/225
Adults 1/1733 46163 1/208
Exp 3: VLP-LCMV
1 week 1/9263 6261 1/463
Adults 1/3623 20425 1/435
Exp 4: VLP-LCMV 
CD4-depletiond
1 week Control 1/8924 7396 1/446
1 week CD4-depleted 1/11242 5960 1/562
a One-week-old and adult mice were immunized with 10 g of VLP-
LCMV. CTLp frequencies were assessed 2 weeks later, after in vitro
restimulation, as described in Material and Methods.
b CTLp frequencies were expressed as the mean of the frequencies
obtained in various immunization groups.
c Total CTLp per spleen and the frequency of LCMV-specific CTLp
per CD8 T cells were calculated based on total numbers of spleno-
cytes or CD8 T cells present at time of sacrifice, respectively.
d For in vivo depletion of CD4 T cells (Exp. 4), mice were injected i.p.
with 300 g of anti-CD4 (GK1.5) mAb on days 1, 0, 1, 7 and 11
of the immunization scheme, and results were similar in a second
experiment.
FIG. 2. Frequency of IFN--secreting CD8T cells following neonatal
and adult VLP-LCMV immunization. One-week-old and adult BALB/c
mice were immunized i.p. with 10 g of VLP-LCMV or VLP-ctrl. Two
weeks after immunization, splenocytes were harvested and restimu-
lated in vitro during 4 days with LCMV118–132, prior to analysis of the
frequency of IFN--secreting cells in individual mice by ELISPOT, as
described in Material and Methods. When indicated, 10 g/ml of
anti-CD8 (H35.17.2) mAb was added into the ELISPOT plates. Data are
expressed as the number of SFC per million of splenocytes in wells
containing LCMV118–132 with SFC in wells without LCMV118–132 subtracted.
Error bars depict standard deviations from 6 to 8 mice. Results are
representative of 3 experiments. SFC in wells without LCMV118–132 were
less than 5.
FIG. 3. Avidity of adult and early-life LCMV-specific CTL. Two weeks
after VLP-LCMV immunization of one-week-old or adult mice, spleno-
cytes were pooled by immunization group and restimulated in vitro with
the LCMV118–132 peptide as in Fig. 1. Cytotoxic activity was measured
with 51Cr-labeled P815 targets cells pulsed with various concentrations
of LCMV118–132 peptide. Data represent the means of percent specific
lysis from duplicate wells obtained at a 6:1 effector/target ratio. Results
are representative of two experiments.
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CTL responses to neonatal VLP-LCMV immunization
are CD4 T cell-independent
CD4 T cells, and in particular via CD40–CD40L inter-
action, play an important role in inducing CTL responses
by activating APC through costimulation (Bennett et al.,
1998; Schoenberger et al., 1998). To assess the role of
neonatal CD4 T cells in the activation of neonatal CTL
responses, we asked whether early-life CTL responses
to VLP-LCMV could be induced in the absence of CD4
T cells in vivo. One-week-old mice were injected i.p. with
300 g of anti-CD4 (GK1.5) MAb on days -1, 0, 1, 7
and 11 of the immunization schedule (Buller et al.,
1987). This resulted in90% depletion of CD4 T cells in
GK1.5-treated mice (not shown). CTL responses were
analyzed under limiting dilution conditions on Day 14
after immunization (as described in Material and Meth-
ods). In vivo CD4 T cell-depletion did not abrogate
LCMV-specific CTL responses, and CTLp remained sta-
tistically similar to those induced in control non-depleted
1-week-old mice (Table 1, exp. 4). Therefore, as previ-
ously demonstrated in adults (Sedlik et al., 1997), early-
life immunization with VLP-LCMV induces CD4 T cell-
independent CTL responses even at 1 week of age.
Antiviral protection through neonatal VLP-LCMV
immunization
Are neonatally induced CTL efficient in protecting im-
munized mice from viral challenge? This question was
assessed by challenge with LCMV-WE two weeks after
immunization of 1-week-old and adult BALB/c mice. Mice
were challenged intravenously with 200 pfu of LCMV-WE
strain and sacrificed 4 days later for determination of
splenic virus titers (Wirth et al., 2000). As expected, high
virus titers were observed in all mice immunized with
VLP-ctrl, regardless of age at immunization (Fig. 4). In
contrast, viral titers were strongly reduced in mice im-
munized with VLP-LCMV at 1 week of age or as adults
(Fig. 4). The majority of immunized mice were free of
detectable virus in the spleen. Thus, neonatally induced
anti-LCMV118–132 T cells have the same protective poten-
tial against viral challenge as those induced in adult life.
DISCUSSION
In this study, we demonstrate that neonatal immuniza-
tion with a non-replicating parvovirus-like particle deliv-
ery system induces antigen-specific CD8 cytotoxic T
cells that are similar to those elicited by adult immuni-
zation in all functional aspects amenable to analysis:
cytotoxic activity, frequency of IFN--secreting cells, cy-
totoxic precursor cell frequencies, in vitro avidity for
antigen and protection against viral challenge. These
CTL responses are elicited within 2 weeks of a single
immunization, in the absence of adjuvant and in the
absence of CD4 T cells.
In recent years, DNA vaccines (Bot, 2000) and live
replicating viral vaccines (Franchini et al., 2001; Kovarik
et al., 2001; Siegrist, 2001) were shown to circumvent the
limitations of early-life CTL responses in murine models
of neonatal and early life immunization, in contrast to
inactivated or non-replicating viral vectors. This was also
achieved by certain adjuvants, such as CpG-oligonucle-
otides (Brazolot Millan et al., 1998; Kovarik et al., 1999)
which are capable of strong neonatal APC activation via
Toll-like-receptor-mediated recognition (Hemmi et al.,
2000). We report here, for the first time, that adult-like
antiviral CTL responses may be elicited in early life by a
non-replicating antigen-delivery system, without the
need for adjuvant. VLP-LCMV immunization induced
strong cytotoxic responses, characterized by similar fre-
quencies of LCMV118–132-specific CTL precursors, as well
as similar frequencies of IFN--producing CD8 T cells
following neonatal and adult immunization. This may be
an important point for adult-like viral clearance since
small differences in antigen-specific CD8 T cell num-
bers have been demonstrated to lead to an inability to
clear polyoma virus infection in susceptible newborn
mice (Moser et al., 2001). Neonatally induced CTL were
also qualitatively similar to those induced in adults, as
demonstrated by their IFN--production and their similar
in vitro avidity for peptide-pulsed target cells, an impor-
tant determinant of protective capacity (Alexander-Miller
et al., 1996; Derby et al., 2001; Sedlik et al., 2000; Speiser
et al., 1992). Importantly, they were already detected, and
protective, 14 days after a single immunization. In con-
trast to previous reports using DNA vaccines or replicat-
ing vectors which persist in vivo during several weeks,
FIG. 4. Protective efficacy of VLP-LCMV immunization against
LCMV-WE challenge. One-week-old and adult mice were immunized
i.p. with10 g of VLP-LCMV or VLP-ctrl. Two weeks after immunization,
mice were injected intravenously with 200 pfu of LCMV-WE. LCMV-WE
viral titers were assessed in the spleen 4 days after challenge, as
described in Material and Methods. Virus titers are expressed as
plaque forming units (pfu)/gram of spleen tissue. Each diamond rep-
resents an individual mouse. The dotted line represents the assay
cutoff. Results are representative of 2 experiments.
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and are thus still present at time of greater immune
competence, or to reports only assessing neonatal in-
duction of CTL responses at several weeks of age, our
observations demonstrate unequivocally the compe-
tence of VLP-induced neonatal T cells to rapidly mount
protective responses, an essential element for the induc-
tion of protection as soon as possible after birth.
A potential limitation of our study is that we were
unable to detect LCMV-specific CD8 T cells directly ex
vivo, whether by assessing cytotoxicity, intracellular
IFN- producing cells or tetramer-binding cells (not
shown), either in adults or neonates. This is in accor-
dance with previous observations of the much lower
frequency of CD8 T cells elicited by a single immuni-
zation with non-replicating vaccines compared to viral
infection. We thus cannot exclude that in vitro restimula-
tion did not modulate CD8 T cell frequency and/or
characteristics. However, regardless of the assay used,
CTL responses assessed in neonates and in adults were
always similar. In addition, the true functional compe-
tence of neonatal CD8 T cells is directly demonstrated
by their in vivo protective capacity.
Why are PPV-VLP so successful in the generation of
early-life CTL responses? VLP are promising novel vac-
cine candidates, combining high immunogenicity with
lack of detectable toxicity in the absence of adjuvants,
while inducing neutralizing antibody and CTL responses
in a number of murine model systems (Breitburd et al.,
1995; Kirnbauer et al., 1992; Sedlik et al., 2000; Sedlik et
al., 1999; Sedlik et al., 1997; Suzich et al., 1995). Early
clinical trials have already confirmed some of these
properties in humans (Ball et al., 1999; Evans et al., 2001;
Harro et al., 2001). One important feature of PPV-VLP is
their ability to ablate the requirement for adjuvantation as
well as for CD4 T cell help in adult mice (Sedlik et al.,
2000). We show here that this is also true in the immature
immune system. LCMV118–132-specific CD4
 T cell cyto-
kine responses were not detected in our assays (data
not shown), despite the fact that the LCMV118–132 peptide
contains a weak CD4 T cell determinant as well as its
strong CD8 T cell determinant. In any case, VLP-spe-
cific or LCMV-specific CD4 T cells, if present, are not
required for the induction of LCMV118–132-reactive CTL, as
demonstrated by the lack of inhibition by in vivo CD4 T
cell-depletion in early-life (our data) or adult (Sedlik et al.,
2000) CTL responses.
The remarkable capability of PPV-VLP to ablate the
requirement for CD4 T cell help in adult mice has been
hypothesized to be due to a strong and direct activation
of APC, in particular DC (Lo-Man et al., 1998; Sedlik et al.,
2000). Human papillomavirus-like particles were recently
shown to be efficiently internalized by adult DC, inducing
their phenotypic maturation and production of inflamma-
tory cytokines (Lenz et al., 2001). We have found this to
be also true for the PPV-VLP used in our study. Indeed, in
vivo, PPV-VLPs are very efficiently captured by dendritic
cells and induce phenotypic maturation as well as ex-
pression of new cell surface markers (Moron et al.,
2002).
Induction of adult-like Th1 and CTL neonatal re-
sponses has been suggested to depend on the extent of
neonatal APC activation and/or of neonatal APC-T cell
interactions (Adkins, 1999). LPS-activation of cord-blood
derived human DC results in limited IL-12 production
(Goriely et al., 2001) and could lead to preferential induc-
tion of CD4 Th2 neonatal responses and/or limitation of
Th1 responses, therefore inhibiting CTL induction. On
the other hand, it has recently been demonstrated that
purified neonatal DCs are perfectly able, when loaded
with a synthetic peptide containing a CTL epitope and
injected to adult mice, to efficiently prime specific CTL
responses (Dadaglio et al., 2002). Our results suggest
that neonatal APC may be stimulated in vivo by PPV-VLP
so as to induce adult-like CTL responses, even without
CD4 T cell help. Another hypothesis is that limitations of
early-life CTL responses to conventional vaccines may
result from an active inhibition/deviation mediated by the
neonatal environment, such as through preferential in-
duction of CD4 Th2 neonatal cytokine responses. Our
preliminary observations with another—CD4 T cell de-
pendent—antigen delivery system suggest that neonatal
CTL responses are indeed susceptible to inhibition by
concomitantly induced CD4 Th2 responses (manuscript
in preparation). Whether the limited induction of neonatal
CTL responses to conventional antigens result from ac-
tivation of neonatal APC and/or from limited or deviated
CD4 T cell responses, the APC activation capacity and
CD4 T cell independence of PPV-VLP identifies them as
safe and potent antigen delivery systems for induction of
neonatal and early-life cytotoxic responses to intracellu-
lar pathogens.
MATERIALS AND METHODS
Mice, virus, and peptide
Specific pathogen-free adult BALB/c inbred mice were
purchased from Biological Research Laboratories (Fu-
l¨insdorf, Switzerland), kept under specific pathogen free
conditions at the W.H.O. Center for Neonatal Vaccinol-
ogy, and manipulated according to National and Euro-
pean guidelines. Breeding cages were checked daily for
new births, and the day of birth was recorded as the day
the litter was found. Pups were kept with mothers until
weaning at the age of 4 weeks. Adult mice were used at
8–12 weeks of age. LCMV strain WE was originally ob-
tained as triple-plaque-purified stock from Dr. F. Leh-
mann-Grube (Heinrich-Pette Institut, Hamburg, Ger-
many). The RPQASGVYMGNLTAQ synthetic peptide car-
rying the p118–132 sequence from the LCMV strain WE
nucleoprotein (Adkins, 1999; Schulz et al., 1989) was
obtained commercially.
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Preparation of chimeric VLP expressing the LCMV
p118–132 peptide
The recombinant VLP-LCMV and control VLP were
obtained from Ingenasa (Madrid, Spain) after construc-
tion, production and purification as previously described
in details (Sedlik et al., 1997). Briefly, the PPV:VP2 gene
was expressed either with the LCMV p118–132 peptide
sequence (VLP-LCMV) or without this sequence (VLP-
ctrl) in a baculovirus vector system. After infection of Sf9
insect cells, VLPs were purified by salt precipitation with
20% ammonium sulfate followed by dialysis. Character-
ization of VLP-LCMV and VLP-ctrl obtained by CsCl sed-
imentation analysis and electron microscopy revealed
properties identical to those of native virions. The mo-
lecular weight of the LCMV peptide represents 3% of that
of VLP-LCMV.
Immunization and in vivo depletion of CD4 T cells
Mice were immunized i.p. in groups of 6 to 8 at 1 week
of age (neonatal immunization) or as adults (controls),
with a single injection of 10 g of VLP-LCMV or VLP-ctrl
in the absence of adjuvant. Where indicated, mice were
injected i.p. with 300 g of anti-CD4 (GK1.5) mAb pre-
pared from ascitic fluid (Swain et al., 1984) on days1, 0,
1,7 and11 of immunization. This resulted in greater
than 90% CD4 T cell-depletion in GK1.5-treated mice, as
controlled by FACS analysis.
Quantification of cytotoxic responses and CTL
precursor frequencies
Splenocytes were harvested 2 weeks after immuniza-
tion. Equal numbers of splenocytes from individual mice
were pooled and cultured as bulk or under limiting dilu-
tion conditions as described (Barrios et al., 1996b).
Briefly, control bulk cultures containing 50  106 spleno-
cytes from immune mice were incubated with 25  106
irradiated (2500 rad) syngenic spleen cells and 2 M of
LCMV118–132 in RPMI 1640, supplemented with HEPES,
amino acids, antibiotics, and 10% fetal calf serum (medi-
um). They were tested on Day 5 by adding varying num-
ber of effector cells to 105 51Cr-labeled P815-pulsed (H-2d)
target cells pulsed with 50 M of LCMV118–132 or incu-
bated in medium alone. After 5 h of incubation, cell
culture supernatants were harvested for determination of
activity in a -counter. The percentage of specific lysis
was calculated as ((experimental c.p.m.  spontaneous
c.p.m.)/(total c.p.m. spontaneous c.p.m.)) 100. Data
shown are averages from duplicate wells. Standard de-
viation from the average was always 5%. Spontaneous
release and total release were determined from target
cells incubated with medium alone or after the addition
of 100 l of 1M HCl, respectively. For limiting dilution
assay, varying numbers of responding cells were dis-
pensed into 96 round-bottomed microwells together with
5 105 irradiated syngeneic stimulator spleen cells, 2
M/ml of LCMV118–132 CTL peptide, and medium with EL-4
supernatant as a source of IL-2 (final IL-2 concentration:
30 Units/ml). Fresh medium containing IL-2 was added
on Day 7. Individual wells were tested on Day 10 for CTL
activity. 51Cr-labeled (H-2d) P815 target cells (105) were
added to each well for a 5-h incubation at 37°C. Spon-
taneous release and total release were determined from
target cells incubated with medium alone or after the
addition of 100 l of 1M HCl, respectively. Cell superna-
tants were harvested for determination of radioactivity in
a gamma counter. Wells with a 51Cr-release content su-
perior to the mean value 5 SD of the radioactivity
measured in the supernatant of targets cells alone were
counted as positive wells. CTL precursor (CTLp) frequen-
cies, which represent the mean frequency for the mice
whose cells were initially pooled, were determined by
the intersection of the regression line of the frequency of
negative wells with the cut-off frequency of 37% (Barrios
et al., 1996b). The CTLp total numbers and the frequency
of LCMV-specific CD8 T cells were calculated based on
the numbers of splenocytes and of CD8 T cells (identi-
fied by FACS analyses), respectively, from spleens of
mice at time of challenge (3 weeks, adults).
ELISPOT assay of LCMV118–132-specific CD8
 T cells
producing IFN-
The ELISPOT assay was adapted from Miyahira et al.
(Miyahira et al., 1995) for detection of LCMV-specific
IFN- secreting T cells. Nitrocellulose microplates (Mil-
lipore) were coated with 5 g/ml rat anti-mouse IFN-
antibody (clone R46A2, Pharmingen). Spleen cells were
restimulated in vitro with LCMV118–132 during 4 days,
washed and dispensed at four twofold dilutions in ELIS-
POT wells in medium containing 30 U/ml of IL-2 (EL-4
supernatant). The cells were exposed to 105 irradiated
(8000 rad) MHC class II negative P815 cells that had
been pulsed with 50 M of LCMV118–132 or medium alone
(control P815) prior to a 24–28 h incubation at 37°. When
indicated, 10 g/ml of anti-CD8 (H35.17.2) mAbs (Pierres
et al., 1982) was added into the wells. The plates were
then washed, incubated overnight at 4°C with 1 g/ml
biotinylated anti-mouse IFN- antibody (clone XMG,
Pharmingen) followed by peroxydase-conjugated Extra-
vidin. Spots were developed by adding freshly prepared
substrate buffer (0.3 mg/ml of 3 amino-9-ethyl-carbazole
and 0.03% H2O2 in 0.1 M sodium acetate pH 4.8). IFN-
spot forming cells (SFC) were counted using the KS
ELISPOT System (Zeiss, Hallbergmoos, Germany) and
expressed as spots/million spleen cells.
Assessment of protective antiviral effect
BALB/c mice were injected intravenously with 200
plaque-forming units (pfu) of LCMV-WE. Four days after
challenge, mice were sacrificed and virus titer deter-
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mined in the spleen as described elsewhere in details
(Wirth et al., 2000). Briefly, spleens were homogenized in
4 ml glass tubes and spun at 1700 g for 10 min at 4°C.
Serial 10-fold dilution of homogenized supernatants were
incubated in 24-well plates coated with the adherent
fibrosarcoma MC57G cell line. After absorption and 48 h
of culture under methylcellulose overlay, cellular mono-
layers were fixed, permeabilized, and stained with mono-
clonal rat anti-LCMV antibody and peroxidase-labeled
second step antibody. Virus titers are expressed as pfu
per gram of spleen. The detection limit for this plaque
assay was 0.5 pfu/mg spleen.
Statistical Analysis
Significance analysis between results obtained from
various groups of mice was performed by using the
Mann–Whitney U test. Probability values  0.05 were
considered insignificant.
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